Medtronic, Edwards and Abbott presented positive data as TAVR, TEER and renal denervation innovations continue to arrive. The 34th Transcatheter Cardiovascular Therapeutics (TCT) conference took place in Boston this past week and a ton of big names made waves with their technologies and innovations. Medtronic, Abbott, Edwards and Boston Scientific represent a few of the […]
Edwards Lifesciences
Edwards TEER therapy proves safe and effective in head-to-head trial with Abbott MitraClip
Edwards Lifesciences (NYSE:EW) announced data confirming its transcatheter edge-to-edge repair (TEER) as safe and effective. CLASP IID compared Edwards’ Pascal system and Abbott’s MitraClip system. The study determined that the two contemporary TEER therapies are safe and effective in patients with degenerative mitral regurgitation (DMR). Results from the trial were presented at the 34th Transcatheter […]
Edwards wins FDA approval for Pascal Precision transcatheter valve repair system
Edwards Lifesciences (NYSE:EW) announced today that the FDA approved its Pascal Precision system for patients with degenerative mitral regurgitation (DMR). The implant and transcatheter delivery system represent Edwards’ bid to compete with Abbott and its MitraClip in the DMR treatment space. Irvine, California-based Edwards Lifesciences designed its Pascal Precision system for precision transcatheter edge-to-edge repair […]
Edwards launches Sapien 3 Ultra Resilia heart valve following FDA approval
Edwards Lifesciences (NYSE:EW) announced today that it launched its next-gen Sapien 3 Ultra Resilia transcatheter heart valve. Irvine, California-based Edwards launched the valve following a recent FDA approval. It incorporates the company’s Resilia tissue technology in the transcatheter aortic valve repair (TAVR) device. Resilia, a bovine pericardial tissue treated with anti-calcification technology, serves as the […]
10 big earnings stories from the last quarter: How are medtech stocks doing now?
Economic uncertainty appears to have produced a wide variety of medtech earnings stories during the most recent round of quarterly results. Some medical device companies received massive boosts from their quarterly performance, while others saw their stocks sink amid missed projections and other various issues. The phrase “macroeconomic headwinds” was a common phrase. Medtech faces […]
Edwards Lifesciences misses in Q2, lowers guidance
Edwards Lifesciences (NYSE:EW) shares are down after hours on second-quarter results that missed the consensus forecast on Wall Street, with the cardio device company reducing 2022 guidance amid foreign exchange headwinds and hospital staffing challenges. The Irvine, California–based company earned $406.4 million, or 65¢ per share, off $1.37 billion for the three months ended June […]
Edwards Lifesciences shares fall on Street-beating Q1 results
Edwards Lifesciences (NYSE: EW) posted first-quarter results today that beat the consensus forecast on Wall Street. It also reaffirmed its outlook for the rest of the year, with CEO Michael Mussallem saying, “We are hopeful the worst of the pandemic is behind us.” The Irvine, California–based cardio device company reported profits of $373.6 million, or […]
FDA approves Edwards Lifesciences’ tissue-based mitral valve replacement
Edwards Lifesciences (NYSE:EW) announced today that the FDA approved its Mitris Resilia tissue valve replacement system. Irvine, California-based Edwards designed the Mitris Resilia valve with a saddle-shaped sewing cuff that mimics the asymmetric shape of the native mitral valve. In addition, it features a low-profile frame for avoiding obstruction of the left ventricular outflow tract […]
These 10 medtech companies’ stocks performed best in 2021
Following a year like no other in 2020, 2021 was when many looked to rebound — including the medtech industry. A number of medtech companies followed up a challenging, pandemic-enveloped year with impressive performances. Plenty of them had already proven in 2020 that they were capable of a quick bounce-back. Here are 10 medtech companies […]
Edwards Lifesciences misses on Q4 earnings as omicron hammers hospitals
Edwards Lifesciences (NYSE:EW) posted fourth-quarter results that fell short of the consensus forecast on Wall Street, but reaffirmed its outlook for 2022. The Irvine, California-based heart device company yesterday evening reported profits of $335.3 million — or $0.53 per diluted share — on sales of $1.33 billion for the three months ended Dec. 31, 2021, […]
FDA approves Edwards Lifesciences Sapien 3 with Alterra for pulmonary regurgitation
Edwards Lifesciences (NYSE:EW) announced today that it received FDA approval for the use of its Sapien 3 transcatheter valve with the Alterra adaptive prestent. Irvine, California-based Edwards garnered the FDA nod for use of the Sapien 3 with Alterra for patients with severe pulmonary regurgitation. The Sapien 3 transcatheter pulmonary valve (TPV) system combines the […]
